Gastrointestinal Drugs Market By Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Antiemetic and Antinauseants, Anti-inflammatory Drugs, Biologics, and Antispasmodic), By Route of Administration (Oral, Parenteral and Rectal), By Disorder Type (Gastro-esophageal Reflux Disease, Inflammatory Bowel Disease, and Irritable Bowel Syndrome), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) And By Geographic Regions (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) – Global Market Analysis, Trends, Opportunity and Forecast, 2023-2032
Market Size and Overview:
The gastrointestinal drugs market size is poised to reach USD 82.9 billion by the end of 2032, growing at a CAGR of 5.0% during the forecast period, i.e., 2023 – 2032. In the year 2022, the industry size of gastrointestinal drugs market was USD 50.9 billion. The reason behind the growth can be attributed to the increasing prevalence of gastrointestinal problems inclusive of inflammatory bowel sickness, gastroesophageal reflux disorder, and irritable bowel syndrome, technological advancements, arrival of personalized medicine and precision healing procedures, the developing older population and changing dietary conduct have similarly fueled the demand for gastrointestinal drugs. The marketplace incorporates a wide range of products. The market is highly competitive with key players striving to meet evolving customer demands.
Gastrointestinal Drugs Market: Report Scope
Base Year Market Size
Forecast Year Market Size
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Antiemetic and Antinauseants
- Anti-inflammatory drugs
- Others (Antispasmodic etc.)
Route of Administration
- Gastro Esophageal Reflux Disease
- Inflammatory Bowel Disease
- Irritable Bowel Syndrome
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
On the basis of drug class in the gastrointestinal drugs market the acid neutralizers segment accounted the highest market share in 2022. The drug class with the highest market share in the gastrointestinal drugs market is acid neutralizers. Acid neutralizers are drugs that work by means of neutralizing the acid in the stomach. They are used to deal with heartburn, acid reflux, and other situations caused by extra gut acid. The marketplace proportion of acid neutralizers is so high because they're a completely powerful remedy for heartburn and acid reflux. They are also exceedingly safe and feature few side outcomes.
North America stands as one of the major markets for gastrointestinal drugs, driven through the emphasis on healthcare. Additionally high prevalence of gastrointestinal disorders makes contributions to the region’s dominance. The United States, primarily, is a key contributor on this marketplace. Europe is one of the leading marketplaces for gastrointestinal drugs because of the regions with a mix of hospital and clinic users. The European market showcases a developing interest in natural remedies and alternative therapies, fueled by consumer preferences for non-pharmaceutical treatments. According to a nationwide study carried out in France, GI therapeutic tablets (GTDs) are appreciably prescribed. The study analyzed compensation information for fifty seven million population and determined that the frequency of people with as a minimum one GTD prescription changed into 29.5%
The Asia Pacific gastrointestinal drugs market is estimated to witness significant growth, during the forecast timeframe led by, rapid urbanization, increasing disposable incomes, and a growing awareness of gastrointestinal disorders. The demand for gastrointestinal drugs is anticipated to rise in countries like China and India, given their expanding healthcare industries and rising prevalence of gastrointestinal disorders among urban residents. Latin America and the Middle East and Africa display steady growth inside the gastrointestinal drugs market, fueled via urban development, a rising middle class, and a growing demand for healthcare services, focus on healthcare infrastructure development and an increasing emphasis on preventive care in both hospital and homecare settings in these regions. Key participants to the market's growth in these areas encompass Brazil, Mexico, the United Arab Emirates, and South Africa.
The growing prevalence of gastrointestinal problems which include inflammatory bowel disorder, gastroesophageal reflux disorder, and irritable bowel syndrome propel the demand for effectual and dependable medications. Additionally, technological advancements have led to the development of recent medications with stepped forward efficacy and fortification profiles, attracting healthcare professionals and patients alike. The growing reputation of opportunity curative procedures and herbal treatments also contributes to market increase. The developing growing aging population and changing dietary habits offer tremendous increase potential. As people age, the threat of gastrointestinal disorders increases, and the demand for pills and treatments rises. Additionally, the shift in the direction of more healthy diets and life aligns with the increasing emphasis on preventive care and well-being. The expanding healthcare industry, mainly in developing regions, drives the demand for gastrointestinal drugs. Healthcare centers necessitate the advanced treatments and technologies, boosting the sales of medicine which includes proton pump inhibitors, antidiarrheals, and laxatives. Over-the-counter (OTC) drugs are becoming more and more famous because of their comfort and affordability. The arrival of personalized medicine and precision healing procedures has converted the market panorama. Personalized medicinal drug offers tailored remedies based on person affected person traits, enhancing treatment efficacy and affected person consequences, riding market surge.
High cost of drugs and emergence of alternative therapies are hindering the growth of market. In developing regions, this factor has resulted in limited demand for product. Moreover, the need for more research and development is also restricting the growth of market.
The gastrointestinal drugs market is poised by several main corporations, each making big contributions to the industry through their sturdy market presence and progressive product offerings. Among these principal players are Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc, AbbVie Inc., Valeant Pharmaceuticals Inc., Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., Sanofi. And other players. These essential players constantly try and revamp their marketplace percentage and meet the desires of a diverse investor base. Their competitive techniques encompass product innovation, forging strategic partnerships, undertaking mergers and acquisitions, and increasing their distribution networks.
In March 2023, Takeda Pharmaceuticals announced that it had acquired Shire plc for $62 billion.
In February 2023, Novo Nordisk A/S announced that it had launched a new insulin product called Tresiba.